• Home
  • Clarivate
  • The API Landscape - Reshoring, Trading & Sourcing Dynamics
Video
21 Jun 2021

The API Landscape - Reshoring, Trading & Sourcing Dynamics

Watch Video

This webinar originally aired as part of CPHI Discover - 17-28 May 2021

THIS IS A LIVE STREAM SESSION - After broadcast it will be available to view on-demand for the remainder of the event.

API manufacturing has always been about innovating to cater for shifting demand patterns, but the recent coronavirus pandemic has raised further questions about manufacturing hubs and consistency of supply. Are we on the brink of a major shift in API production?

  • The complexity of globally interconnected pharmaceutical supply chains
  • Market pressures to modernize API supply chains through digitization
  • The advantage of increased real-time visibility in its supply chain
  • The role of trading in the API supply chain
  • Offshore vs Onshore Manufacturing
  • Could reshoring represent an opportunity for boosting innovation and new manufacturing technologies to compete effectively and take a greener approach?

    • This session will feature a live Q&A where you can put your questions to our expert panel.

    Read more Show less
    Content provided by our supplier

    Clarivate

    • US
    • 2015
      On CPHI since
    • 5000+
      Employees
    Company types
    Academic/Research
    Consultancy
    IT/Software solution provider
    Primary activities
    Analytical Services
    Technology
    View company profile

    Other Content from Clarivate (2)

    • API market tested by COVID-19 but pandemic is accelerating adoption of supply chain solutions: CPHI panel

      News API market tested by COVID-19 but pandemic is accelerating adoption of supply chain solutions: CPHI panel

      CPHI Discover panel of industry experts discusses impact of COVID-19 on API manufacturing and trading as well as the controversial topic of reshoring production
      21 May 2021
    • Biosimilars in Oncology

      Webinar Biosimilars in Oncology

      The availability of of biologic therapies to treat oncology disease conditions has led to improved clinical outcomes, but the high cost can create barriers and disparities in treatment access, and therefore outcomes. The use of biosimilars can improve patients' access to care by decreasing treatment costs and creating price competition between the originator product and biosimilar competitors. Watch this Clarivate webinar on-demand now to understand the following: What is the current landscape of biosimilars in oncology? How do biosimilar approvals and market access differ between the United States and Europe? What is interchangeability and what is its impact? What are the barriers to uptake of biosimilars in oncology? What is the future of biosimilars in oncology?